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ABSTRACT 
Mutations of HSPB5 (also known as 
CRYAB or αB-crystallin), a bona fide heat shock 
protein and molecular chaperone encoded by the 
HSPB5 (crystallin, alpha B) gene, are linked to 
various multisystem disorders featuring variable 
combinations of cataracts, cardiomyopathy, and 
skeletal myopathy. This study aims at 
investigating the pathological mechanisms 
involved in an early onset myofibrillar myopathy 
manifesting in a child harboring a homozygous 
recessive mutation in HSPB5, 343delT. To study 
HSPB5 343delT protein dynamics, we utilize 
model cell culture systems including induced 
pluripotent stem cells (iPSCs) derived from the 
343delT patient (343delT/343delT) along with 
isogenic, heterozygous, gene-corrected control 
cells (WT KI/343delT), and BHK21 cells, a cell 
line lacking endogenous HSPB5 expression. 
343delT/343delT and WT KI/343delT iPSC-
derived skeletal myotubes (iSKMs) and 
cardiomyocytes (iCMs) did not express detectable 
levels of 343delT protein, contributable to extreme 
insolubility of the mutant protein. Overexpression 
 http://www.jbc.org/cgi/doi/10.1074/jbc.M116.730481The latest version is at 
JBC Papers in Press. Published on May 19, 2016 as Manuscript M116.730481
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of HSPB5 343delT resulted in insoluble mutant 
protein aggregates and induction of a cellular 
stress response. Co-expression of 343delT with 
WT prevented visible aggregation of 343delT and 
improved its solubility. Additionally, in vitro 
refolding of 343delT in the presence of WT 
rescued its solubility. We demonstrate an 
interaction between WT and 343delT both in vitro 
and within cells. These data support a loss of 
function model for the myopathy observed in the 
patient, as the insoluble mutant would be 
unavailable to perform normal functions of 
HSPB5, though additional gain-of-function effects 
of the mutant protein cannot be excluded. 
Additionally, our data highlights the solubilization 
of 343delT by WT, concordant with the recessive 
inheritance of the disease and absence of 
symptoms in carrier individuals. 
 
 
 HSPB5 (also known as CRYAB or αB-
crystallin) is a small molecular weight heat shock 
protein (sHSP)
#
 encoded by the HSPB5 gene and 
functions as a molecular chaperone. Its promoter 
contains a heat shock element (HSE), a stress-
responsive binding site of heat shock transcription 
factor 1 (HSF1), which functionally upregulates 
the expression of HSPB5. Increased levels of 
HSPB5 can then go on to provide distinct 
cytoprotective effects engaged in restoring cellular 
homeostasis (reviewed in (1,2)). Additionally, 
HSPB5 contains tissue-specific enhancer elements 
in its promoter that allow constitutive, high 
expression in the lens, heart, and skeletal muscle 
(3,4).  
 As a member of the sHSP family, HSPB5 
contains a well-conserved central “α-crystallin” 
domain (ACD), flanked by N- and C-terminal 
regions (5). The ACDs dimerize, and assemble to 
form a polydisperse ensemble of oligomers, 
largely through dynamic interactions mediated by 
the terminal regions (6). The isolated ACD has 
been shown to have potent chaperone activity in 
vitro (7), and it is hypothesized that it might 
become exposed within the context of the wild-
type protein in a manner regulated by 
phosphorylation (8) or cellular stress directly (9). 
The HSPB5 ACD contains two hydrophobic 
grooves, one between the β4 and β8 strands, and 
the other at the dimer interface, both of which 
serve as putative binding sites for chaperone 
action (10). In addition, evidence also points at the 
involvement of the N-terminus in target binding 
(11). As such, current data suggests HSPB5 is a 
dynamic protein that is flexible in how it interacts 
with its diverse range of clients. 
In striated muscle, HSPB5 acts as a 
chaperone for important structural client proteins 
including desmin (12-14), titin (15-18), and actin 
(14,19), a property that becomes particularly 
important under conditions of pathology or stress. 
HSPB5/HSPB2 double knockout (DKO) mice 
exhibit progressive skeletal myopathy throughout 
life (20) with impact on cardiac muscle only 
observed under conditions of exogenous stress 
(21,22). More recently, a requirement for HSPB5 
in muscle homeostasis has been demonstrated via 
modulation of argonaute 2 activity (23). DKO 
mice show reduced basal levels of skeletal muscle 
progenitor cells, or satellite cells, and defective 
muscle regeneration with cellular injury (23).  
 Multiple mutations in HSPB5 are linked to 
human pathologies affecting the lens, heart, 
skeletal muscle, or some combination thereof with 
the underlying disease mechanism(s) only partially 
understood (reviewed in (24,25)). These mutations 
are either dominant or recessive and have variable 
penetrance and expressivity. Of the known 
mutations in HSPB5 linked with (cardio-) 
myopathy, all but one result in aberrant protein 
aggregation of the mutant protein (reviewed in 
(25)). For the well-studied R120G mutation in 
HSPB5, the aggregates are thought to sequester 
other metastable proteins such as desmin (26-28). 
The relative contribution of loss versus gain-of-
toxic function effects remain unclear for specific 
mutations. 
 An enhanced understanding of HSPB5 as 
a chaperone is needed to inform therapy 
development. Herein, we have investigated a 
recessive mutation in HSPB5, 343delT, found in a 
patient who presented at age four months with 
profound muscle stiffness, persistent creatine 
kinase elevation, and histopathological features of 
a myofibrillar myopathy (29). This homozygous 
recessive, single base deletion results in a 
frameshift and formation of a premature stop 
codon following addition of 14 missense residues 
(S115fs129X). The truncated protein is predicted 
to contain residues 1-115, having lost the C-
 at K
IN
G
'S CO
LLEG
E LO
N
D
O
N
 on June 8, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Defects of 343delT HSPB5 
 
3 
 
terminal extension, as well as a significant portion 
of the ACD. The patient’s skeletal muscle biopsy 
shows dense, irregular staining of HSPB5, 
detectable only by an antibody recognizing the N-
terminus of HSPB5 (NT-HSPB5). This band runs 
at the predicted molecular weight of 15 kDa on a 
western blot, smaller than the 22 kDa wildtype 
HSPB5 (WT) protein (29). Additionally, the 
biopsy shows intense, irregular staining of desmin 
and myotilin. At presentation, the patient exhibited 
neither signs of an associated cardiomyopathy nor 
cataracts, though with age, these symptoms may 
develop. Of note, the non-consanguineous parents, 
each heterozygous for 343delT, have no known 
symptoms attributed to this mutation, however, 
potential development of late-onset symptoms 
cannot be excluded. 
 To understand 343delT protein dynamics 
and their contribution to disease, we have 
incorporated the use of induced pluripotent stem 
cells (iPSCs) (30) derived from the patient as a 
unique system to permit study of endogenous 
343delT protein within cell types of interest. 
Additionally, we used systems of overexpression 
in a cell line that lacks endogenous HSPB5 
expression (reviewed in (31)), due to the recessive 
nature of the mutation, as well as in vitro analysis 
of 343delT. Herein we describe our findings that 
provide insights into molecular defects of 343delT 
in disease pathogenesis.  
 
RESULTS 
Generation of iPSCs for Investigation of 
343delT— Fig. 1A shows the family pedigree of 
the patient harboring the homozygous, recessive 
343delT mutation. Non-consanguineous parents 
are each heterozygous for the mutation and are 
asymptomatic, while the homozygous 343delT 
patient exhibits a severe, infantile-onset myopathy 
(29). To examine effects of 343delT (strategy 
outlined in Fig. 1B), we generated iPSCs from the 
patient’s dermal fibroblasts through four factor 
reprogramming. Isogenic, heterozygous gene-
corrected control cells were then engineered from 
the patient iPSCs with a strategy adapted from 
Yusa and colleagues (32) through zinc finger 
nuclease (ZFN)-stimulated homologous 
recombination (see Experimental Procedures). 
Genotypes of both the patient (343delT/343delT) 
and heterozygous wildtype knock-in control (WT 
KI/343delT) iPSCs are outlined in Fig. 1B, and 
were confirmed through direct Sanger sequencing 
(Fig. 1C). Both iPSC lines expressed relevant 
pluripotency markers including NANOG, stage-
specific embryonic antigen 4 (SSEA-4), octamer-
binding protein 4 (OCT-4), and TRA-1-81 at the 
protein level (Fig. 1D-E) and NANOG, OCT-4 
(POU5F1), SOX2, and TRA-1-60 at the RNA level 
(Fig. 1F). In vitro EZ sphere differentiations of 
both cell lines resulted in upregulation of markers 
from all three germ layers (Fig. 1G). Karyotypes 
were normal (Fig. 1H). These data validate the use 
of generated iPSC lines for further investigations. 
343delT Protein is not Detectable in 
iSKMs or iCMs though RNA is Present—
Validated iPSC lines were differentiated into 
skeletal myotubes (iSKMs) and cardiomyocytes 
(iCMs) using established protocols (see 
Experimental Procedures). iCMs contracted 
rhythmically in the dish, stained positive for 
cardiomyocyte markers including Troponin T 
(TnT) (Fig. 2A) and exhibited cardiomyocyte-like 
action potential profiles (Fig. 2C). iSKMs elongate 
as they mature in culture, many appear multi-
nucleated, some cells can be observed to twitch 
spontaneously, and they stain positive for muscle 
markers including TnT (Fig. 2B and 4A) and 
desmin (Fig. 4B). No obvious phenotypic 
differences were observed between WT 
KI/343delT and 343delT/343delT iCMs or iSKMs 
when characterizing cell differentiation in this 
way. 
 The major difference observed between 
the muscle differentiated cell lines was a complete 
lack of detectable 343delT protein both through 
immunocytochemistry (Fig. 2A-B) and western 
blot (Fig. 2D-E) in the 343delT/343delT line when 
probed with and NT HSPB5 antibody. In the WT 
KI/343delT control, predicted to express both a 22 
kDa-sized WT protein and a 15 kDa-sized 
343delT protein, only the WT form of the protein 
is detectable (Fig. 2D-E), indicating lack of 
detectable 343delT is not due to immaturity of the 
cells. This result was surprising to us as the muscle 
biopsy from the patient showed dense, irregular 
staining of HSPB5 through immunohistochemistry 
and a 15 kDa-sized protein detectable by western 
blot with the NT HSPB5 antibody (29). Lack of 
343delT protein was confirmed in a second iPSC 
line derived from the patient as well as the 
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isogenic, heterozygous gene-corrected control line 
derived from that iPSC line (Supplementary 
Figure S1). Additionally, homozygous knockin of 
the 343delT mutation into the endogenous HSPB5 
locus of an iPSC line derived from an unrelated, 
healthy individual also exhibited a complete lack 
of detectable 343delT protein (manuscript in 
preparation).  
As 343delT protein was not detectable, we 
next investigated whether this was due to defects 
in RNA levels. The 343delT transcript is not 
predicted to be a target for nonsense-mediate 
mRNA decay (NMD) as the premature stop codon 
is downstream of the final exon-exon junction 
complex (33). Therefore we hypothesized 343delT 
transcript levels would be comparable to WT. 
Quantitative real-time PCR (qRT-PCR) of iCMs 
and iSKMs revealed expression of HSPB5 mRNA 
in both WT KI/343delT and 343delT/343delT 
(Fig. 2F-G). HSPB5 mRNA levels may differ 
depending on the efficiency of differentiation, 
which varies between iPSC lines and 
differentiation attempts, as noted by differences in 
expression of the muscle-specific gene Troponin T 
(TNNT2) (Fig. 2F-G). Therefore, though the level 
of HSPB5 mRNA cannot be directly compared 
between samples, we confirm that 343delT mRNA 
is present. Additionally, in contrast to an unstable 
mRNA control, MYC, levels of HSPB5 mRNA did 
not decline in WT KI/343delT or 343delT/343delT 
iCMs with treatment of actinomycin D to inhibit 
transcription over 24 hours (Supplementary Figure 
S2), indicating similar transcript stability between 
WT and 343delT. These results show the defect in 
343delT protein expression is not due to deficient 
transcript levels. 
Lack of 343delT Protein is not Due to 
Degradation, microRNA Targeting, or Defective 
Translation— To further investigate the reason for 
lack of 343delT protein detection, we next 
examined protein degradation as a possible 
mechanism. iCMs were treated with the 
proteasomal inhibitor MG132 (34), (Fig. 3A).  
In contrast to the increase in the short-lived cell 
cycle inhibitor p21 with MG132 treatment (35), 
343delT protein (15 kDa) remained undetectable 
in both WT KI/343delT and 343delT/343delT with 
inhibition of proteasomal degradation. Inhibition 
of autophagosome maturation with bafilomycin 
A1 for 12 hours (36) was also insufficient to evoke 
343delT protein detection in iCMs, though LC3-II 
(lower band) increased as expected with treatment 
(Supplementary Figure S3A). Additionally, 
treatment of 343delT/343delT iSKMs with the 
proteasomal inhibitor bortezomib for up to 48 
hours (37) (Supplementary Figure S3B) or MG132 
for 12 hours (Supplementary Figure S3C) and 
inhibition of autophagosome maturation with 
bafilomycin A1 for 12 hours (Supplementary 
Figure S3C) were also insufficient to evoke 
343delT detection. These data suggest that the lack 
of detectable 343delT protein is not due to 
degradation by the proteasome or autophagy. 
Complimentary experiments of overexpression of 
343delT in a human breast cancer cell line (MCF7 
cells), showed that both inhibition of the 
proteasome (MG132) and autophagy (bafilomycin 
A1) resulted in slight increases of 343delT protein 
(Supplementary Figure S3D-E). This result 
suggests that 343delT protein is likely degraded to 
some extent by the proteasome and autophagy, but 
this is not the major cause for our inability to 
detect 343delT protein in our iPSC model. 
Another possibility we considered is that 
343delT mRNA is differentially targeted 
compared with WT by a microRNA that inhibits 
translation. To examine this possibility, we 
transfected iCMs with siRNA to knockdown dicer, 
the protein responsible for processing pre-
microRNAs into mature microRNAs (38). Though 
knockdown of dicer was confirmed through 
decreased levels of dicer protein and elevated 
levels of c-MYC, a known target of dicer-
dependent microRNAs (39), we were unable to 
detect 343delT protein in either WT KI/343delT or 
343delT/343delT (Fig. 3B). This result suggests 
that 343delT is not differentially targeted by a 
dicer-dependent microRNA. 
To confirm there is no inherent defect in 
the translation efficiency of 343delT compared 
with WT, we performed an in vitro 
transcription/translation assay using rabbit 
reticulocyte lysate labeling translated proteins with 
35
S-L-methionine and 
35
S-L-cysteine. We utilized 
a plasmid containing N-terminally MYC-tagged 
versions of WT (pCS2-MYC-WT) and 343delT 
(pCS2-MYC-343delT) and an SP6 promoter as the 
template for this reaction. Both WT and 343delT 
are visible after 30 minutes of incubation and 
increase after 90 minutes (Fig. 3C). No significant 
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difference is observed between WT and 343delT 
in the rate of synthesis over time (21.8 ± 3.4 and 
19.1 ± 6.9, respectively) of the recombinant 
protein. This result shows 343delT is translated 
efficiently, at least in this reticulocyte lysate.  
In toto, these results demonstrate that lack 
of detectable 343delT protein in iCMs and iSKMs 
generated from 343delT/343delT and WT 
KI/343delT is not attributable to proteasomal 
degradation, autophagic degradation, microRNA 
targeting, or defective translation.  
343delT Forms Insoluble Protein 
Aggregates and Induces a Cellular Stress 
Response when Overexpressed— The results 
presented above utilizing iCMs and iSKMs show 
an absence of detectable 343delT protein. The 
presence of mutant protein in the patient’s biopsy 
specimen suggests that accumulation of 343delT 
in the affected tissue may contribute to disease. 
For this reason, we attempted to simulate these 
conditions with our model to determine if high 
levels of 343delT expression would result in 
aggregation in muscle cells.  
We transiently transfected N-terminally 
MYC-tagged WT or 343delT constructs (pCMV-
MYC-WT and pCMV-MYC-343delT) into 
343delT/343delT iSKMs. Overexpression of 
343delT resulted in aggregation in iSKMs marked 
by TnT (Fig. 4A) or desmin (Fig. 4B), whereas 
overexpression of WT resulted in diffuse, 
cytoplasmic staining (Fig. 4A-B). 343delT 
aggregates exclude TnT and desmin. Similar 
aggregates of 343delT were observed with 
overexpression in 343delT/343delT iCMs (data 
not shown). These results indicate that at high 
levels, 343delT forms aggregates in muscle cells. 
 Since overexpression of 343delT in 
iSKMs recapitulates aggregation observed in the 
patient’s biopsy, we examined if overexpression in 
non-muscle cell lines also results in 343delT 
aggregation. Transfection is difficult in iCMs and 
iSKMs and variances in differentiation efficiency 
may impact results, making overexpression studies 
in commercially available cells lines that lack 
endogenous HSPB5 expression, such as BHK21 
cells (baby hamster kidney fibroblasts), more 
appealing. Overexpression of pCMV-MYC-
343delT forms cytoplasmic aggregates in BHK21 
cells (Fig. 4C), which are detectable with both NT 
HSPB5 and MYC-tag antibodies. Absence of 
additional cells staining with NT HSPB5 relative 
to MYC-tag exemplifies the lack of endogenous 
HSPB5 expression. Aggregates in BHK21 cells 
typically appear in the perinuclear region and look 
similar to aggregates observed with 
overexpression in iSKMs (Fig. 4A-B). 
Overexpression of pCMV-MYC-WT in BHK21 
cells results in diffuse, cytoplasmic staining (Fig. 
4C). These experiments provide proof-of-concept 
for the use of overexpression of 343delT in 
BHK21 cells as a platform to investigate 343delT 
aggregation and protein dynamics. 
 We noted that levels of 343delT protein 
expression were consistently lower than WT by 
immunocytochemistry and western blot when 
overexpressed in all cell lines tested. We 
confirmed equal transfection efficiency through 
co-transfection with a pCMV-dsRed plasmid (data 
not shown). Additionally, levels of WT and 
343delT mRNA were assessed between 2-24 hours 
after transfection and determined to be similar 
(Supplementary Figure S4A). RNA levels 
correlated with transfection efficiency for the WT 
construct (Supplementary Figure S4B). 
Transfection with either WT or 343delT neither 
impacted cell proliferation nor viability 
(Supplementary Figure S5A-B) when compared 
with empty vector (EV) transfection over a similar 
period. These results indicate transfection 
efficiencies and RNA levels were equal and cell 
proliferation and viability were unaffected by 
transfection. 
The metastable desmin protein is a known 
client for HSPB5 (12-14) and is present in 
aggregates in patients with desmin-related (cardio-
) myopathy (25,26,40). Though 343delT 
aggregates did not colocalize with desmin in 
iSKMs, we wanted to examine this in BHK21 
cells, which express endogenous desmin as well 
(26,31). 343delT aggregates in BHK21 cells 
colocalize with desmin in some (Fig. 4D, middle 
panel), but not all cells (Fig. 4D, bottom panel), 
potentially indicating stochastic incorporation of 
desmin into aggregates. 
 Misfolded proteins and protein aggregates 
are triggers for the induction of a cellular stress 
response driven by the master regulatory 
transcription factor HSF1(41). This response 
results in the upregulation of genes whose 
promoters contain heat shock response elements 
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including HSP70 (as reviewed in (2)). Indeed, 
overexpression of 343delT in BHK21 cells 
resulted in induction of HSP70 in some, but not 
all, transfected cells (Fig. 4E), while WT does not 
result in HSP70 induction (Fig. 4E). We further 
confirmed this induction by western blot (Fig. 4F). 
These results indicate that 343delT can induce a 
cellular stress response when overexpressed. 
Consistent upregulation of HSP70 in 
343delT/343delT iCMs under basal conditions 
was not observed (data not shown), indicating 
perhaps the detectable, aggregated form of 
343delT and/or the presence of other proteins in 
the aggregates is required for upregulation of 
HSP70. 
 Altogether, these results show the ability 
of 343delT to form visible, cytoplasmic aggregates 
when overexpressed in muscle and non-muscle 
cells, with potentially stochastic incorporation of 
desmin into these aggregates, at least in non-
muscle cells. Additionally, HSP70 induction 
demonstrates disruption in overall protein 
homeostasis with overexpression of 343delT.  
Co-Expression with WT Solubilizes 
343delT— As 343delT is a recessively inherited 
mutation, in order to mimic the unaffected 
heterozygous parents, we co-transfected HA-
tagged WT and MYC-tagged 343delT constructs 
(pCMV-HA-WT HSPB5 and pCMV-MYC-
343delT HSPB5) into cell lines in equimolar 
ratios. In the presence of WT, 343delT no longer 
forms aggregates in BHK21 cells (Fig. 5A, bottom 
panel). Additionally, when expressed alone, 
343delT was present almost entirely in the 
insoluble fraction (99 ± 1%, mean ± s.d., n=3), 
while when co-expressed with WT, the percent 
insoluble 343delT was reduced 6.6 fold (15 ± 6%, 
mean ± s.d., n=3, p-value of <0.01 as calculated by 
student’s t-test) (Fig. 5B-C). The percentage of 
insoluble 343delT was quantified using the 15 
kDa-sized band ([insoluble] density *100 / 
([insoluble] density + [soluble] density )). Larger 
molecular weight bands may be post-
translationally modified forms of the protein; 
inclusion of these bands in analysis does not 
impact relative percent insoluble 343delT. These 
results indicate that the presence of WT shifts 
343delT from the insoluble to the soluble fraction. 
To determine if 343delT and WT are 
interacting, we co-transfected HA-tagged WT and 
MYC-tagged 343delT and performed co-
immunoprecipitation (Co-IP). IP of HA resulted in 
the pull down of MYC-tagged 343delT only in the 
co-transfected sample (Fig. 5D). Reciprocally, IP 
of MYC resulted in the pull down of HA-tagged 
WT only in the co-transfected sample (Fig. 5D). 
The insoluble pellet fraction demonstrated that 
much of the 343delT protein, when transfected 
alone, was insoluble (Fig. 5D), consistent with the 
idea that WT solubilizes 343delT. These results 
demonstrate an interaction between WT and 
343delT proteins within the cell. 
343delT Solubility: In vitro and In vivo— 
In line with overexpression in mammalian cell 
lines, the overexpression of recombinant 343delT 
in E.coli resulted in an insoluble product 
exclusively found in inclusion bodies (Fig. 6A). 
Refolding of 343delT in the absence of WT 
predominantly led to the formation of insoluble 
aggregates (Fig. 6B). Conversely, the presence of 
an excess of WT during the entire refolding 
process resulted in the formation of a soluble 
product (Fig. 6B). This mixture eluted from gel 
filtration in a single peak with a slight shoulder at 
an elution volume of approximately 10 mL, 
slightly earlier than refolded WT, which eluted at 
10.5 mL (Fig. 6C). SDS-PAGE of the resulting 
fractions showed the co-elution of 343delT (14.7 
kDa) with WT (20.2 kDa) across the entire peak, 
whilst only a single band at the WT mass was 
visible in the control (Fig. 6C, upper panel). To 
obtain a higher resolution view of the oligomers 
formed, we performed native mass spectrometry 
(42). A spectrum of WT reveals a broad region of 
signal centered around 10,000 m/z, resulting from 
the overlap of a large number of charge states (Fig. 
6D), and consistent with a polydisperse ensemble 
of oligomers (43). A spectrum obtained for the 
343delT:WT mixture at identical mass 
spectrometry  conditions reveals an additional 
charge series at approximately 2,000 m/z, 
corresponding to a mass of 14,695 Da, which can 
be assigned to the monomeric form of 343delT 
(Fig. 6D). Interestingly, the charge states 
populated are relatively low, indicative of a largely 
folded conformation of the 343delT monomers 
free in solution. Examination of the high m/z 
region of the spectrum for WT allows the 
assignment of overlapping charge-state envelopes 
to the oligomers comprising the ensemble. 
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Strikingly, many additional features are observed 
in the spectra for the 343delT:WT mixture (Fig. 
6D, insert). The complexity of the spectrum is 
such that individual oligomers cannot be directly 
identified, but by comparison to the WT data it is 
clear that they cannot be explained by integer 
stochiometries of WT HSPB5, but rather that an 
ensemble of heteroligomers is present, resulting 
from a direct interaction between the two proteins. 
These in vitro data further support the notion that 
WT solubilizes 343delT through a direct 
interaction.  
We hypothesized that extreme insolubility 
of 343delT was responsible for our inability to 
detect the mutant protein in iSKMs and iCMs, and 
for lower levels of 343delT compared with WT 
upon overexpression. We have excluded many 
reasons for the absence of detectable 343delT 
protein noted above, including mRNA instability, 
degradation by the proteasome or autophagy, 
targeting by a dicer-dependent microRNA, and 
defective translation. Decreased detectable 
343delT protein compared with WT was 
consistently observed both through analyses by 
western blot and immunocytochemistry. We tested 
additional lysis buffers to determine if we could 
detect 343delT by western blot including RIPA 
buffer, 100% formic acid, and 8 M urea plus 2% 
SDS. We observed a consistent lack of 343delT 
protein in iCMs with all tested buffers (data not 
shown).  
Addition of a small ubiquitin-related 
modifier (SUMO) to proteins has been shown to 
enhance their solubility (44,45). To directly test 
our hypothesis that insolubility of 343delT is the 
reason for low levels of detection with 
overexpression, we generated SUMO-HSPB5 
fusion constructs. These plasmids contain a 
version of WT and 343delT HSPB5 that are N-
terminally MYC-tagged followed by SUMO, 
preceding the HSPB5 variant. We used a non-
cleavable version of SUMO3 Q89P (46) in this 
construct to prevent removal of SUMO by 
endogenous deSUMOylases. MYC-tag only 
versions of the constructs were used as controls. 
Expression of SUMOylated constructs in BHK21 
cells results in a 130 ± 60 and 5 ± 1 (mean ± s.d.) 
fold increase in 343delT and WT, respectively 
(Fig. 6E). The larger increase of 343delT 
compared with WT through the addition of SUMO 
(p<0.05, calculated by student’s t-test) suggests 
that the increase in mutant protein is likely not due 
to inherent stabilization and/or enhanced 
transcription/translation of proteins by SUMO 
addition; if this were the case, similar increases in 
WT and 343delT would be expected. Elevated 
detection of 343delT was also observed with 
overexpression of 343delT and SUMOylated 
343delT in 343delT/343delT iCMs resulting in 
811 ± 218 fold (mean ± s.d.) enhanced detection of 
the SUMOylated protein by western blot (Fig. 6F). 
These results suggest that our suboptimal ability to 
detect 343delT is due to extreme insolubility of the 
mutant protein in both non-muscle and muscle 
cells. 
 
DISCUSSION 
Altogether, the data presented here 
describe molecular defects observed with disease-
causing 343delT. Although mRNA is unaffected, 
basal levels of 343delT protein in iCMs or iSKMs 
were undetectable in both WT KI/343delT and 
343delT/343delT cell lines. Detection of the WT-
sized protein, but not the truncated 343delT-sized 
protein in the heterozygous WT KI/343delT iPSC-
derived cells indicates that absence of 343delT is 
not due to lack of maturation. Several possibilities 
such as, proteasomal degradation, autophagic 
degradation, Dicer-dependent microRNA 
targeting, and inherent translational defects were 
examined and proved unlikely mechanisms 
responsible for lack of detectable 343delT protein. 
Overexpression of 343delT consistently resulted in 
much lower levels of protein compared with WT 
as well. Greatly enhanced detection of 343delT 
when fused to SUMO3 Q89P, a non-cleavable 
form of SUMO known to enhance protein 
solubility, is consistent with extreme insolubility 
of 343delT as the reason for lack of protein 
detection.  
It is conceivable that insoluble 343delT 
would be unavailable to perform essential, normal 
functions of HSPB5 in the muscle cells, suggestive 
that loss of HSPB5 function contributes to 
myopathy in the patient harboring homozygous 
343delT. HSPB5 specifically plays key chaperone 
roles for proteostasis and protein quality control, 
differentiation, and maintenance in muscle cells 
(12-23). Loss of these or other functions of 
HSPB5 may leave myotubes vulnerable to stress, 
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prone to muscle breakdown with increased usage, 
and/or have an impact on regeneration of skeletal 
muscle from satellite cells. Although absent at 
presentation, the early onset of the skeletal 
myopathy in the patient does not preclude later 
development of cardiac manifestations. 
Though 343delT protein is observed in the 
patient skeletal muscle biopsy, it does appear at 
lower levels when compared with a control 
individual (29). Nonetheless, endogenous 
detection of the mutant protein was not observed 
in our iPSC-derived cells. Potentially our model 
does not recapitulate 343delT expression observed 
in the patient for reasons related to the culture 
environment (pH differences, 2D cell culture vs. 
3D tissue structure, oxygen levels, etc.), stress 
(contraction, muscle turnover), variability in 
experimental techniques, age- and tissue-
dependent, and other factors. This may illustrate 
inherent limitations of iPSCs in modeling diseases 
due to an accumulation of stressors over time, also 
corresponding to the observation that the patient 
was entirely normal until disease onset at 4 months 
of age. Therefore, we hypothesize that the iPSCs 
recapitulates what may have occurred early in the 
patient, i.e. prior to disease manifestation. 343delT 
may be packaged into a completely insoluble state 
when expressed at basal levels, and its 
accumulation over time could result in 343delT 
surpassing a threshold thereby allowing detection. 
The potential change in protein status may or may 
not contribute to disease. It is of interest that the 
severity and early onset nature of the autosomal 
recessive disease in the 343delT patient is not 
consistent with the DKO mouse (20), which 
develops progressive myopathy into adulthood. 
We recognize these differences could be due to 
species variation and/or the DKO mouse also 
lacking HSPB2. Alternatively, the presence of 
343delT protein could exacerbate the phenotypes 
observed in the complete loss of function scenario 
(DKO mouse). 
 Co-aggregation of 343delT with desmin 
was observed upon overexpression of 343delT in 
some but not all BHK21 cells, but was not 
observed with overexpression in iSKMs. Other 
mutations in HSPB5 such as R120G (26,40) result 
in co-aggregation of the mutant protein with 
desmin and patients are termed to have desmin-
related (cardio-) myopathy. The stochastic 
accumulation of desmin in 343delT aggregates is 
likely due to loss of 343delT chaperone function 
towards aggregation-prone desmin resulting in the 
two proteins clustered together, amongst other 
proteins, in aggregates. The extent of desmin 
accumulation in aggregates likely depends on 
overall protein homeostasis within the cell. The 
finding that overexpression of 343delT induced 
elevated levels of HSP70 in BHK21 cells is 
consistent with cells suffering from an imbalance 
in protein homeostasis. We did not observe 
consistently elevated HSP70 levels in 
343delT/343delT iCMs under basal conditions, 
which indicates that the presence of detectable 
343delT (i.e. the visible aggregated form) and 
potentially other proteins present in the aggregates 
are required for disruption of protein homeostasis.  
The recessive nature of 343delT led us to 
investigate the interaction between 343delT and 
WT HSPB5. It is unknown if the heterozygous 
parents, who are non-consanguineous and healthy, 
express detectable levels of the 343delT protein. 
Potentially, expression of 343delT in the 
heterozygous state may not be detrimental as we 
have shown increased solubility of 343delT and 
loss of aggregate formation upon co-expression 
with equimolar WT. Our Co-IP experiments 
demonstrate an interaction between 343delT and 
WT within the cell. Together these data suggest 
that WT solubilizes 343delT. Additionally, the 
presence of WT during refolding of 343delT 
rescues the protein from forming insoluble 
aggregates in vitro. The shift in elution volume 
during size exclusion and co-elution of the 
proteins as observed by SDS-PAGE suggest the 
formation of a complex between WT and 343delT, 
which is confirmed directly by native mass 
spectrometry experiments. The observation of a 
large proportion of what appears, from the absence 
of highly charged 343delT species, to be solution 
phase monomeric 343delT in the mass spectrum 
suggests a labile interaction, especially under the 
conditions used, consistent with a chaperone-like 
interaction. The ability of WT to solubilize 
343delT and the presence of unaffected WT 
protein to perform normal cellular functions likely 
result in the parents being asymptomatic. 
Overall our data support loss of HSPB5 
function as a likely mechanism contributing to the 
myopathy. Given the substantial number of protein 
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aggregation diseases, the findings reported here 
have direct implications for understanding the 
mechanisms of variable expressivity of both 
disease susceptibility and resistance. Though we 
cannot exclude the presence of the mutant protein 
directly contributing to disease, any detrimental 
effects of the 343delT protein would likely be 
ameliorated by the presence of WT through 
solubilization. Exogenous expression of WT 
HSPB5 by a gene therapy approach may therefore 
improve symptoms in mutant HSPB5-induced 
myopathy. Design of effective delivery methods 
for exogenous chaperones to the tissue or gene/cell 
therapy would be necessary for this treatment. 
 
EXPERIMENTAL PROCEDURES 
Reprogramming Patient Dermal 
Fibroblasts to iPSCs— Dermal fibroblasts were 
isolated from the patient containing the 343delT 
mutation (29) with written consent of the patient’s 
mother and with research ethics committee 
approval at Guy's & St Thomas' NHS Foundation 
Trust (London, UK) for biobank storage and 
transfer of samples for use in an ethically 
approved research project. Fibroblast culture and 
further research in the laboratory was performed 
with appropriate IRB approval at the University of 
Utah (Salt Lake City, UT) and the Medical 
College of Wisconsin (Milwaukee, WI) for use of 
human cells. Dermal fibroblasts expanded in 
DMEM supplemented with 10% FBS and 100 u 
penicillin/100ug streptomycin/ml media (P/S) (all 
from Life Technologies) were reprogrammed into 
induced pluripotent stem cells (iPSCs) through 
transduction with 4 retroviruses carrying the genes 
OCT-4, SOX2, c-MYC, and KLF4 as previously 
described (30). Following transduction, transduced 
fibroblasts were seeded onto SNL feeder cells 
(Cell Biolabs) that were mitotically inactivated 
through treatment with Mitomycin C (ATCC), in 
ESC medium composed of Knockout DMEM 
supplemented with 20% Knockout Serum 
Replacement, Minimum Essential Medium-Non-
Essential Amino Acids (MEM-NEAA), 2 mM L-
glutamine (all from Life Technologies), P/S, 0.1 
mM β-mercaptoethanol (Sigma), 10 ng/ml human 
bFGF (Cell Signaling), and 50 ng/ml L-ascorbic 
acid (Sigma). Resulting iPSC clones were 
manually picked and maintained on feeder cells in 
ESC medium for four passages before 
transitioning to feeder-free culture as described 
below. 
iPSC Culture— iPSCs were routinely 
cultured in feeder-free conditions on matrigel 
(Corning)-coated dishes with mTeSR1 (Stem Cell 
Technologies) or StemMACS iPS-Brew XF 
(Miltenyi Biotec). Cells were passaged every 3-4 
days using Accutase (Life Technologies) and 
seeded in media containing 10 μM ROCK 
inhibitor (Y-27632, Selleck) for 24 hours 
following passaging. 
Gene-Editing in iPSCs, Genotyping, and 
Sequencing— iPSCs derived from the 
homozygous recessive 343delT patient 
(343delT/343delT) were gene-corrected to 
generate heterozygous 343delT iPSCs (WT 
KI/343delT) using a protocol modified from a 
previously defined strategy that involves 
knockin/excision of a selection cassette (32). 
Briefly, zinc finger nucleases (ZFNs) were 
designed and generated by Sigma (CompoZr 
Custom Zinc Finger Nucleases). The targeting 
vector was designed and synthesized using Gene 
Art (Life Technologies) containing a portion of the 
WT HSPB5 sequence with a silent mutation (435 
G>T) to generate a TTAA site for piggyBac 
excision. The puromycin/thymidine kinase 
selection cassette driven by the PGK promoter 
(PGK-puroΔtk) and flanked by piggyBac repeats 
was cloned from the pPB-CAG-OSKM-puDtk 
vector (Sanger Institute, UK) into the targeting 
vector through In-Fusion Cloning (CloneTech). 
Components were transfected into iPSCs using a 
4D-Nucleofector and P4 Nucleofector Solution 
with program CB-150 (Lonza) followed by 
seeding onto SNL feeder cells and selection with 
0.5-1 μg/ml puromycin (InvivoGen) from days 5-
12 post-transfection. Resulting puromycin 
resistant clones were manually picked and 
genotyped. Heterozygous knockin clones were 
selected for excision of the selection cassette and 
transfected with an excision only piggyBac 
transposase (PBx, Transposagen) followed by 
negative selection with 0.5 μM Ganciclovir 
(Cayman Chemicals). Resulting colonies were 
picked and genotyped. PCR products from WT 
KI/343delT iPSCs were cloned into a TOPO 
vector (Life Technologies) and plasmids were 
isolated from bacterial colonies and Sanger 
sequenced by Retrogen (San Diego, CA) to 
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confirm heterozygosity for the 343delT mutation 
and incorporation of the engineered silent 
mutation. WT KI/343delT iPSCs were expanded 
and transitioned to feeder-free culture as described 
above. 
Immunocytochemistry— Cells on 4% 
paraformaldehyde (Sigma) fixed glass coverslips 
were permeabolized with 0.1% triton-X 100 
(Sigma), blocked with 3% bovine serum albumin 
(Ultrapure BSA- Cell Signaling), and stained 
appropriately before finally mounting with 
Ultracruz Hard Set Mounting Media plus DAPI 
(Santa Cruz). Primary antibodies: NANOG (Cell 
Signaling 4903p, 1:200), SSEA-4 (Stem Cell 
Technologies 60062AD, 1:40), OCT-4 (Cell 
Signaling 2840, 1:400), TRA-1-81 (Abcam 
ab16289, 1:100), N-terminal (NT) HSPB5 
(NovaCastra ABCrys513, Leica, 1:100), troponin 
T (TnT, Abcam 45932, 1:500), MYC-tag (Cell 
Signaling 2278, 1:100), desmin (Dako M0760, 
1:100), HSP70 (Stress Marq SMC-100A/B, 
1:100), and HA-tag (Invivogen ab-hatag, 1:500). 
Secondary antibodies: AlexaFluor 488 donkey 
anti-rabbit IgG and AlexaFluor 555 donkey anti-
mouse IgG (Life Technologies, 1:500). Images 
were taken on a Nikon A1 confocal microscope. 
Quantitative Real-Time PCR (qRT-
PCR)— RNA was isolated using PureLink RNA 
MiniPrep Kit (Life Technologies) followed by 
treatment with DNA-free DNA Removal Kit (Life 
Technologies). cDNA was generated using High-
Capacity cDNA Reverse Transcription Kit (Life 
Technologies). qRT-PCR was performed using 
BioRad CFX 96 Thermocycler (BioRad) with 
Qiagen QuaniTect SYBR Green PCR Mix and 
QuantiTect Primer Assays (Qiagen). BioRad CFX 
Manager Software (BioRad) was used for data 
analysis.  
Karyotyping—Performed by Wisconsin 
Diagnostic Laboratories (formerly Dynacare 
Laboratories) (Milwaukee, WI). 
iCM and iSKM Differentiation— iCM 
differentiation was performed using chemical 
modulation of the Wnt pathway modified from a 
previously described protocol (47). Briefly, iPSCs 
at 100% confluency were overlayed with matrigel 
in mTeSR1 or StemMACS iPS-Brew XF media on 
Day-1. D0, cells were treated with 12 μmol/L 
Chir-99021 (Selleck) and 10 ng/ml human 
Activin-A (R & D Systems) in RPMI minus 
insulin medium (RPMI supplemented with 1X 
B27 supplement minus insulin- both from Life 
Technologies). Day 2, media was changed to 
RPMI minus insulin. Day 3, cells were treated 
with 5 μmol/L IWP-2 (Stem Cell Technologies) in 
RPMI minus insulin, with media subsequently 
changed on Day 5 to RPMI minus insulin. Media 
was changed to Complete medium, RPMI 
supplemented with 1X B27 supplement (Life 
Technologies) and P/S on Day 7 and changed 
every 2-3 days following until cells were utilized 
for experiments around Day 30 of differentiation. 
iCMs were passaged prior to experiments using 
TrypLE Express (Life Technologies) and seeded 
in Complete medium containing 10% FBS and 10 
μM ROCK inhibitor on 0.1% gelatin-coated 
surfaces. 
iSKMs were differentiated using the EZ 
sphere protocol as previously described (48). 
Week 5 EZ spheres where treated with Accutase 
and pelleted for qRT-PCR of markers for all three 
germ layers. Week 6 EZ spheres were terminally 
differentiated as previously described (48) for 3 
weeks prior to experiments. Immunocytochemistry 
was performed directly on cells differentiated on 
coverslips. 
Electrophysiology of iCMs—Action 
potentials were recorded using intracellular sharp 
electrodes. Coverslips containing beating clusters 
of iCMs were placed in Tyrodes solution and held 
at physiological temperature with a heated 
recording chamber (TC-344B; Warner 
Instruments). Sharp electrodes were pulled from 
borosilicate glass (FHC, Inc.) using a Sutter Model 
P-97 to resistances of 50-70 MΩ when backfilled 
with 3M KCl. Recordings were acquired using a 
Multiclamp 700B amplifier (Molecular Devices) 
interfaced with a Digidata 1449A (Molecular 
Devices). The pClamp software suite (version 10; 
Molecular Devices) was used for data acquisition 
and analysis. Graphing of representative action 
potentials was performed using Origin software 
(OriginLab). 
Cell Fractionation Assay and Western 
Blot—Detergent soluble, detergent insoluble, and 
whole cell lysate (WCL) fractions were isolated 
and western blots performed as described 
previously (49), except equal amounts of protein 
were separated on Mini-Protean TGX Gels 4-20% 
(BioRad). Primary antibodies: NT HSPB5 
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(NovaCastra ABCrys513, Leica, 1:100), GAPDH 
(Cell Signaling 2118, 1:10,000), p21 (Santa Cruz 
sc-sc397, 1:250), LC3 (Novus NB100-2220, 
1:10,000), dicer (SantaCruz sc-393328, 1:100), c-
MYC N-262 (Santa Cruz sc-764, 1:500), MYC 
9E10 (Santa Cruz sc-40, 1:200), HSP70 (Stress 
Marq SMC-100A/B, 1:1,000), α-tubulin (Santa 
Cruz sc-5546, 1:500), β-actin (Abcam ab6276, 
1:5,000), and HA-tag (Invivogen ab-hatag, 
1:1,000). Quantification of band intensity was 
performed using Image J or Image Lab 5.2.1 
(BioRad) software. 
Inhibition of the Proteasome and 
Autophagosome Maturation— iCMs and iSKMs 
were treated with DMSO, 10 μM MG132 or 10 or 
100 nM bortezomib to inhibit the proteasome, or 
80nM bafilomycin A1 to inhibit autophagosome 
maturation for 12 hours. 
Dicer Knockdown— iCMs were 
transfected with scrambled siRNA control (-), or 
either 40 pmols (+) or 80 pmols (++) siRNA 
targeting dicer (SantaCruz) using Lipofectamine 
RNAi Max (Life Technologies). Samples were 
harvested 72 hours post-transfection. 
HSPB5 Vector Constructs— pCMV N-
terminal MYC-tagged WT and HA-tagged WT 
(pCMV-MYC-WT and pCMV-HA-WT, 
respectively) were generated previously (49). The 
pCMV-MYC-343delT construct was produced by 
in vitro site-directed mutagenesis as described 
previously (49). MYC-WT and MYC-343delT 
were PCR-amplified from pCMV-MYC vectors 
and cloned into a pCS2 vector, which contains an 
SP6 promoter required for TNT assay (see below). 
For SUMOylated constructs, a gBlock Gene 
Fragment (Integrated DNA Technologies) was 
purchased containing the non-cleavable SUMO3 
Q89P sequence obtained from the pcDNA3 MYC-
SUMO3Q89P vector (Addgene Plasmid #48963) 
(46), and cloned into pCMV-MYC-WT and 
343delT constructs. Resulting constructs, pCMV-
MYC-SUMO3 Q89P-WT and pCMV-MYC-
SUMO3 Q89P-343delT, are a fusion in the N to C 
terminal direction of MYC-SUMO3Q89P-WT and 
343delT HSPB5, respectively. 
In vitro Transcription/Translation 
Assay— TNT SP6 Quick Coupled 
Transcription/Translation Systems (Promega) was 
used with EXPRE
35
S
35
S Protein Labeling Mix 
(PerkinElmer) containing both 
35
S-L-methionine 
and 
35
S-L-cysteine. pCS2-MYC-WT and 343delT 
plasmids were used as template DNA in the 
reaction according to the manufacturer’s 
instructions. Samples were subsequently run on a 
12% SDS-PAGE gel, transferred to nitrocellulose 
membranes, and exposed to film at -80ºC. 
Quantification of band intensity was performed 
using Image J software. 
Transfection—iSKMs were transfected 
using Lipofectamine 3000 (Life Technologies) 
according to the manufacturer’s instructions. 
 BHK21 cells (ATCC) were cultured in 
Glasgow media supplemented with 5% tryptose 
phosphate broth (both from Life Technologies), 
15% FBS, and P/S. BHK21 cells were transfected 
with Lipofectamine 3000 according to the 
manufacturer’s instructions. For co-transfection of 
two plasmids, equal amounts of each plasmid were 
used with empty vector (EV) plasmid added to 
single plasmid transfections to control for total 
DNA amount. 
 iCMs were passaged and resuspended in 
P3 nucleofection solution (Lonza) and transected 
using the CA-137 program on the 4D-
Nucleofector System (Lonza). Following 
transfection, cells were seeded onto fibronectin-
coated surfaces (Corning) in Complete media 
supplemented with 10% FBS and ROCK inhibitor. 
Co-Immunoprecipitation—Cell pellets 
were resuspended in RIPA Buffer (Thermo 
Scientific) supplemented with Halt Protease and 
Phosphatase inhibitor (Thermo Scientific), 
sonicated on ice and centrifuged at 4ºC for 10 
minutes at 12,000 x g. A portion was removed 
here for WCL, diluted with 4x XT Sample Buffer, 
and boiled 5 minutes. The remaining WCL was 
used for IP preformed with Protein G Sepharose 4 
Fast Flow Beads (Genesee). Samples were pre-
cleared through incubation with beads for 45 
minutes on a rotisserie shaker at 4 ºC, followed by 
pre-incubation with 200 μg/ml antibody, either 
MYC 9E10 (Santa Cruz sc-40) or HA (Invivogen 
ab-hatag) for 30 minutes at 4ºC with intermittent 
vortexing. Beads were added to sample/antibody 
mixture and incubated on rotisserie shaker for 1 
hour at 4ºC. Bead-bound samples were washed 6 
times with RIPA buffer and finally resuspended in 
RIPA buffer with 4x XT Sample Buffer, boiled 5 
minutes, and centrifuged 30 seconds at 12,000 x g. 
The insoluble pellet, prior to IP, was washed 2 
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times with RIPA buffer, resuspended in 4x XT 
Sample Buffer, boiled 5 minutes, and centrifuged 
30 seconds at 12,000 x g. All fractions were 
loaded onto Mini-Protean TGX Gels 4-20% 
(BioRad). Western blots were performed as 
described above. 
In vitro 343delT Protein Expression, 
Refolding and Purification— The 343delT 
plasmid, purchased from GenScript, was 
transformed into BL21 (DE3) Stratagene Gold 
Competent cells (Agilent Technologies) and plated 
on kanamycin selective plates. A single colony 
was picked and used to inoculate 5mL of LB 
(Fisher). This culture was incubated at 37ºC, 220 
rpm, overnight until a high OD was achieved. 1 L 
LB were then inoculated with 10 mL of the 
overnight culture and grown at 37ºC, 200 rpm, 
until an OD of between 0.6-0.8 was obtained. To 
induce 343delT expression a final concentration of 
0.5 mM IPTG (Merck) was added and cultures 
grown for a further 3 hours before harvesting by 
centrifugation. Cell pellets were then stored at -
80ºC for future use. Cells were thawed, re-
suspended and lysed in 50 mM Tris (Sigma), 
0.1mM EDTA (Sigma), 0.1 mM DTT (Sigma), 0.1 
M NaCl (Sigma), 5% glycerol (Fisher), pH 7.9 
(lysis buffer) containing a cOmplete EDTA free 
protease inhibitor tablet (Roche). Post-clarification 
overexpressed 343delT was shown to reside within 
insoluble inclusion bodies (IB) and not within the 
soluble lysate. The insoluble pellet was re-
suspended in lysis buffer and any remaining cells 
were lysed by an additional sonication step. 
Membrane elements were solubilized by the 
addition of a final concentration of 1% Triton X-
100 (Promega). This preparation was left to 
incubate for 15 minutes on ice before centrifugal 
clarification. Two further washes of the IB pellet 
were carried out in lysis buffer to remove the 
remaining Triton X-100. Clean IB pellets were 
then solubilized in 6 M GuHCl (Sigma), 50 mM 
Tris, 0.1 mM EDTA, 0.1 mM DTT, 5% glycerol, 
pH 7.9 and agitated at room temperature for 1 
hour, with any remaining insoluble material being 
removed by centrifugation. The protein 
concentration of the sample was estimated from 
UV absorbance measurements and 2 molar 
equivalence of WT HSPB5 was added. Protein 
refolding was achieved by gradually reducing the 
concentration of GuHCl by stepwise dialysis, 
initially to 2 M, 1 M and then 0 M to ensure 
refolding was complete. Samples were passed 
through a 0.22 μM Spin X Centrifuge tube (Fisher 
Scientific) and loaded onto a Superdex 200 10/300 
column (GE Healthcare) to further purify and 
buffer exchange into 200 mM ammonium acetate 
(Sigma) pH 6.9. Fractions could then be analyzed 
by SDS-PAGE before being selected for mass 
spectrometry analysis. 
Mass Spectrometry— Complex-containing 
samples were analyzed by nanoelectrospray mass 
spectrometry without the need for further sample 
preparation or concentration. Transmission 
pressures and energies on a Synapt G1 HDMS 
(Waters Corp) were optimized to preserve non-
covalent interactions but to maintain the 
transmission of large assemblies. Spectra were 
obtained using a previously defined protocol (42) 
under the following conditions: capillary 1.5 kV, 
cone 50 V, extractor 3.0 V, trap 8.0 V, transfer 8.0 
V, analyzer pressure 1.58 e
-3
 mBar, backing 
pressure 5.8 e
0
 mBar. All spectra were processed 
and analyzed in MassLynx V4.1. 
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The abbreviations used are: sHSP, small molecular weight heat shock protein; HSE, heat shock element; 
HSF1, heat shock transcription factor 1, ACD, “α-crystallin” domain; DKO, HSPB5/HSPB2 double 
knockout mouse; NT-HSPB5, N-terminus of HSPB5; WT, wildtype HSPB5; iPSCs, induced pluripotent 
stem cells; ZFN, zinc finger nuclease; 343delT/343delT, patient cell line; WT KI/343delT, heterozygous 
wildtype knock-in control cell line; SSEA-4, stage-specific embryonic antigen 4; OCT-4, octamer-
binding protein 4; iSKMs, iPSC-derived skeletal myotubes; iCMs, iPSC-derived cardiomyocytes; TnT, 
Troponin T; NMD, nonsense-mediate mRNA decay; qRT-PCR, quantitative real-time PCR; TNNT2, 
Troponin T; EV, empty vector; s.d., standard deviation; s.e.m., standard error of the mean; Co-IP, 
coimmunoprecipitation; SUMO, small ubiquitin-related modifier;  
 
FIGURE LEGENDS 
 
FIGURE 1. 343delT iPSC generation and pluripotency characterization. A.) Representative pedigree for 
the family of the homozygous recessive 343delT patient. Females are represented by circles, males by 
squares. Filled shapes represent homozygous 343delT. Half-filled shapes represent heterozygous 
343delT. B.) Schematic representation of experimental strategy. Dermal fibroblasts derived from the 
homozygous 343delT patient were reprogrammed into iPSCs (343delT/343delT), with the 343delT 
mutation indicated by the red star. Heterozygous gene-corrected control iPSCs were generated from the 
343delT/343delT iPSCs through gene editing, and have one copy of WT knocked-in to the HSPB5 locus 
(WT KI/343delT). WT KI/343delT and 343delT/343delT iPSCs were differentiated to iPSC-derived 
cardiomyocytes and skeletal myotubes (iCMs and iSKMs, respectively). C.) Direct Sanger sequencing of 
a PCR product covering the region of interest reveals deletion of the T at position 343 (highlighted in 
black) in the 343delT/343delT iPSCs. The PCR product from the WT KI/343delT iPSC line was TOPO-
cloned into a vector and multiple clones were sequenced. Reads showing WT (top) and 343delT (bottom) 
were observed, indicating the WT KI/343delT iPSC line is heterozygous for this mutation. WT 
KI/343delT and 343delT/343delT iPSCs were stained with immunocytochemistry for pluripotency 
markers D.) nanog (red) and SSEA-4 (green) and E.) OCT-4 (red) and TRA-1-81 (green). Nuclei were 
counterstained and merged with DAPI (blue). Size bars indicate 50 μm. F.) qRT-PCR was performed on 
WT KI/343delT and 343delT/343delT iPSCs with the graph depicting mean ± s.e.m. relative expression 
levels of pluripotency markers NANOG, OCT-4, SOX2, and TRA-1-60 normalized to 18s rRNA and 
compared to human dermal fibroblasts (HDF) derived from the patient. G.) WT KI/343delT and 
343delT/343delT iPSCs differentiated to EZ spheres were taken at week 5 of differentiation for qRT-PCR 
analysis with markers of the three-germ layers: endoderm (AFP and GATA4), mesoderm (α-MHC and 
BRACHYURY), and ectoderm (β-III-TUBULIN and VIMENTIN). Graph shows mean ± s.e.m. expression 
values normalized to 18s rRNA and compared to WT KI/343delT iPSCs. H.) 20 proliferating cells were 
counted and fully analyzed using G-banding for each cell line with representative karyotype images 
showing no consistent abnormalities.  
 
FIGURE 2. 343delT protein is not detectable in iSKMs or iCMs though RNA is present. WT KI/343delT 
and 343delT/343delT iPSCs were differentiated to A.) iCMs or B.) iSKMs and stained with antibodies 
that recognized NT HSPB5 (red) and troponin T (TnT, green) and merged with DAPI (blue). Size bars 
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indicate 50 μm. C.) Representative action potentials recorded from spontaneously beating WT 
KI/343delT (Top) and 343delT/343delT iPSCs (Bottom) cardiomyocytes (n=6). Western blot and qRT-
PCR was performed on paired samples derived from WT KI/343delT and 343delT/343delT cells. Western 
blots of whole cell lysate (WCL) from D.) iCMs and E.) iSKMs probed with antibodies that recognize NT 
HSPB5 and GAPDH as a loading control. qRT-PCR of F.) iCMs and G.) iSKMs showing mean ± s.e.m. 
gene expression for HSPB5 and TROPONIN T (TNNT2) normalized to 18s rRNA. Expression is shown as 
fold change compared with undifferentiated iPSCs. 
 
FIGURE 3. Lack of 343delT protein is not due to degradation, microRNA targeting, or disrupted 
translation. A.) WT KI/343delT and 343delT/343delT iCMs were treated with DMSO or 10 μM MG132 
to inhibit the proteasome for 12 hours. Western blots of WCL were probed with antibodies recognizing 
NT HSPB5, p21, and GAPDH. Results are representative of two independent experiments. B.) WT 
KI/343delT and 343delT/343delT iCMs were transfected with scrambled siRNA control (-), or either 40 
pmols (+) or 80 pmols (++) siRNA targeting dicer. Samples were harvested 72 hours post-transfection 
and WCL was run on a western blot and probed with antibodies against NT HSPB5, dicer, c-MYC (N-
262), and GAPDH. C.) Equal amounts of pCSC-MYC-WT and pCS2-MYC-343delT plasmids were input 
into an in vitro transcription/translation (TNT) assay along with 
35
S-labeled methionine/cysteine. Aliquots 
were taken from reactions at 30 and 90 minutes as indicated and separated by SDS-PAGE, transferred to 
nitrocellulose membranes and exposed to film (top). Image is representative of 3 independent experiments 
with quantification (bottom) expressing synthesis over time as arbitrary units indicating band intensity 
showing mean ± s.d. There is no significant difference in the rate of synthesis over time for WT (21.8 ± 
3.4) and 343delT (19.1 ± 6.9) as calculated by student’s t-test (p>0.5). 
 
FIGURE 4. 343delT forms visible aggregates when overexpressed and induces a cellular stress response. 
343delT/343delT iSKMs were transfected with pCMV-MYC-WT or pCMV-MYC-343delT constructs. 
Cells were stained 48 hours post-transfection with antibodies recognizing A.) NT HSPB5 (red) and TnT 
(green) and B.) MYC-tag (green) and desmin (red). Size bars indicates 25 μm. BHK21 cells were 
transfected with pCMV-MYC-WT or pCMV-MYC-343delT constructs for 24 hours and co-stained with 
antibodies against C.) NT HSPB5 (red) and MYC tag (green), D.) MYC-tag (green) and desmin (red), and 
E.) MYC-tag (green) and HSP70 (red). Size bars indicate 50 μm. In all merged immunocytochemistry 
images, nuclei were counterstained and merged with DAPI (blue). Enlargements of the area within the 
white dotted box are shown at the right. Arrows indicate 343delT aggregates. F.) WCL from BHK21 cells 
transfected as above or similarly with pCMV-MYC-empty vector (EV) were analyzed by western blot 
with antibodies recognizing HSP70, MYC (9E10), and α-tubulin as a loading control. Samples were run 
in duplicate. 
 
FIGURE 5. WT co-expression reduces 343delT aggregates and increases solubility of the mutant protein. 
A.) BHK21 cells were transfected with pCMV-HA-WT, pCMV-MYC-343delT, or both (co-transfection) 
and stained with antibodies against HA-tag and MYC-tag after 24 hours. Nuclei were counterstained and 
merged with DAPI (blue). Enlargements of the area within the white dotted box are shown at the right. 
Arrows indicate 343delT aggregates. Size bar indicates 50 μm. B.) BHK21 cells were transfected with 
pCMV-HA-WT, pCMV-HA-WT and pCMV-MYC-343delT (co-transfection), pCMV-MYC-343delT, or 
pCMV-MYC-WT, harvested 24 hours post-transfection, and fractionated into soluble and insoluble 
fractions or whole cell lysate (WCL). Equal amounts of protein were loaded for western blot using an 
anti-MYC (9E10) antibody and an HA-tag antibody with β-actin as a loading control. Image depicts 
representative blots from 3 independent experiments. C.) The percentage of insoluble 343delT, quantified 
using the 15 kDa-sized band ([insoluble] density *100 / ([insoluble] density + [soluble] density )) is shown in the 
bar graph. Insoluble 343delT is reduced 6.6 fold by co-expression with WT (343delT alone = 99 ± 1% 
insoluble 343delT, 343delT + WT = 15 ± 6% insoluble 343delT, mean ± s.d., n=3, p-value of <0.01 as 
calculated by student’s t-test). D.) BHK21 cells transfected as in (B) were harvested after 24 hours for 
Co-IP using RIPA buffer and immunoblotted with anti-HA-tag or anti-MYC (9E10) antibodies. Western 
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blots were performed showing IP fractions as well as WCL and the insoluble fraction (remaining pellet 
from sample solubilized in RIPA buffer) and stained with antibodies against MYC (9E10), HA-tag and α-
tubulin as a loading control.  
 
FIGURE 6. In vitro refolding of 343delT in the presence of WT and SUMOylation in cells rescue 
343delT insolubility. A.) Recombinant 343delT expressed in E.coli was found to accumulate within 
insoluble inclusion bodies (I) and not within the soluble lysate (S). B.) Refolding WT or a 343delT:WT 
mixture resulted in a soluble product that was not removed upon passing through a 0.22 μm filtration 
device. Refolding of 343delT in the absence of WT resulted in aggregates that were removed from 
solution upon filtration. U= unfiltered, F= filtered. C.) 300 µL of refolded WT and refolded 343delT:WT 
mixture from (B) were loaded in subsequent runs onto a Superdex 200 10/300 column (pre-equilibrated 
into 200 mM ammonium acetate pH 6.9). Separation was carried out at a flow rate of 0.4 mL/minute and 
absorbance monitored at 280 nm. The chromatogram for the 343delT:WT mixture (orange) had a slight 
shoulder and was shifted to earlier elution volumes compared to WT alone (purple). 9 µL of fractions 9-
17 were analyzed by SDS-PAGE for each run, alongside molecular weight markers. These revealed the 
co-elution of 343delT with WT. D.) Corresponding fractions from each run in (C) were analyzed by 
means of native mass spectrometry. The control containing WT displayed a complicated overlapping 
signal centered near 10,000 m/z, relating to multiple charge state series of WT oligomers. For the mixture, 
two areas of interest were identified, a region around 10,000 m/z akin to the WT spectra and a charge state 
series at 2,000 m/z. This was identified to correspond to monomeric 343delT (Mw = 14,695 Da). Close 
inspection of the region at high m/z (inset), reveals peaks in the 343delT:WT mixture that cannot arise 
from WT homo-oligomers, but rather correspond to an ensemble of hetero-oligomers comprising both 
HSPB5 components. E.) BHK21 cells were transfected with pCMV-MYC-WT, pCMV-MYC-SUMO3 
Q89P-WT, pCMV-MYC-343delT, or pCMV-MYC-SUMO3 Q89P-343delT, harvested 24 hours post-
transfection, and WCL was isolated. Equal amounts of protein were loaded for western blot using an anti-
MYC (9E10) antibody with β-actin as a loading control. Image depicts a representative blot from 3 
independent experiments with longer exposure shown at the right. Relative increase in WT and 343delT 
proteins with the addition of SUMO is indicated below the respective lanes. WT increased 6 ± 1 fold, 
while 343delT increased 130 ± 60 fold (mean ± s.d. of 3 independent experiments) with a p-value of 
<0.05% as calculated by student’s t-test. F.) 343delT/343delT iCMs were transfected with pCMV-MYC-
343delT or pCMV-MYC-SUMO3 Q89P-343delT and harvested 24 hours post-transfection. Analysis of 
WCL by western blot was performed using an anti-MYC (9E10) antibody with β-actin as a loading 
control with longer exposure shown at the right. Relative increase in 343delT protein with the addition of 
SUMO is indicated (811 ± 218 fold) as mean ± s.d. of 3 independent experiments. 
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SUPPLEMENTARY DATA 
 
Supplementary Figure S1: Lack of 343delT Protein in an Alternate iPSC Line 
An alternate iPSC line derived from 343delT/343delT patient dermal fibroblasts was gene-corrected using 
the same approach as described previously. Both lines were differentiated to iCMs and iSKMs and a 
western blot was performed and probed with antibodies that recognize NT HSPB5 and GAPDH as a 
loading control. 
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Supplementary Figure S2: 343delT Transcript Stability 
To measure HSPB5 transcript stability, iCMs were re-plated on day 27 as described in Experimental 
Procedures and seeded into a 12 well 0.1% gelatin coated plate at 80% confluency. The following day, 
cells were treated with 1μM actinomycin D (Sigma) to inhibit transcription and harvested at indicated 
time points for qRT-PCR. HSPB5 mRNA and MYC (an unstable control mRNA) levels were normalized 
to 18s rRNA and plotted as mean ± s.e.m. expression relative to 0 hour WT KI/343delT sample. Data is 
representative of two independent experiments performed. Decrease in MYC transcript levels from 0-4 
hours indicates the actinomycin D treatment successfully inhibited transcription. HSPB5 levels did not 
decline over 24 hours, indicating transcript stability. The unexpected increase in HSPB5 mRNA levels 
may be explained by incomplete inhibition of transcription by actinomycin D, which acts as a cellular 
stress and upregulates stress response genes including HSPB5. 
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Supplementary Figure S3: Overexpressed 343delT Protein is Degraded by Both the Proteasome 
and Autophagy 
A.) 343delT/343delT iCMs were treated with DMSO or 80 nM bafilomycin A1 to inhibit autophagy for 
12 hours. Western blots of WCL were probed with antibodies recognizing NT HSPB5, LC3, and 
GAPDH. Results are representative of two independent experiments. B.) 343delT/343delT iSKMs were 
treated with DMSO (-) or 10 or 100nM bortezomib for 24 or 48 hours to inhibit the proteasome and 
WCLs were probed by western blot with antibodies recognizing NT HSPB5, p21, and GAPDH. C.) 
343delT/343delT iSKMs were treated with DMSO (-), 80nM bafilomycin A1, or 10μM MG132 for 12 
hours and WCL were run on western blots probed with antibodies recognizing NT HSPB5, LC3, p21, and 
GAPDH. MCF7 cells were transfected with pCMV-MYC-WT or 343delT constructs for 24 hours 
followed by treatment with DMSO, 5 μM MG132, or 80 nM bafilomycin (Baf) for 12 hours. D.) Western 
blots with 5 μg (WT) or 60 μg (343delT) of WCL were stained with antibodies against MYC (9E10) and 
GAPDH as a loading control. Samples are shown in duplicates. Results are representative of two 
independent experiments. E.) 5 μg of protein for each of the same samples in (D) was run on a gel and 
stained with antibodies against p21, LC3, and GAPDH. Both inhibition of the proteasome (MG132) and 
inhibition of autophagosome maturation (Baf) resulted in slightly elevated levels of 343delT.  
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Supplementary Figure S4: Transfection and RNA levels are Equal between WT and 343delT  
A.) MCF7 cells transfected with pCMV-MYC-WT or 343delT HSPB5 constructs were harvested 2, 4, 6, 
or 24 hour after transfection for qRT-PCR. Graph shows mean ± s.e.m. ΔCt values for HSPB5 normalized 
to 18s rRNA from n=3. B.) MCF7 cells were transfected with empty vector (EV) (1 μg) or pCMV-MYC-
WT in increasing amounts (0.01 μg, 0.1 μg, 1 μg). Samples (n=4 for each group) were harvested 24 hours 
after transfection and divided using half for qRT-PCR analysis of gene expression (left graph) and the 
other half fixed and analyzed by flow cytometry (right graph). HSPB5 gene expression is normalized to 
18s rRNA, with the graph expressing mean ± s.e.m. fold change relative to EV. Transfection efficiency 
was analyzed by flow cytometry using anti-MYC-tag (Cell Signaling 2278, 1:500) with the graph 
showing mean ± s.d. percentage of MYC-tag positive cells. Results indicate similar transfection 
efficiencies between WT and 343delT. 
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Supplementary Figure S5: Effects of 343delT Expression on Proliferation and Cell Toxicity 
HEK 293FT cells transfected with EV, myc-tagged WT, or myc-tagged 343delT were harvested after 24 
hours and A.) total cell number as well as B.) percent viable cells by trypan blue staining were counted 
using a Countess Automated Cell Counter (Life Technologies). Graphs depict mean ± s.d. from n=4 for 
each group. Results indicate no impact on cell proliferation or viability with transfection of WT or 
343delT constructs. 
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